Copper-CX-5461: A Novel Liposomal Formulation for a Small Molecule rRNA Synthesis Inhibitor
September 28, 2018 Journal of Controlled Release
Leung, A.W.Y., Anantha, M., Dragowska, W.H., Wehbe, M., and Bally, M.B.

Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase I Inhibitor CX5461
April 25, 2018 Chemistry: a European Journal
Prosser K.E., Leung, A.W.Y., Harrypersad, S., Lewis A.R., Bally, M.B., and Walsby, C.J.

Development of a Copper-Clioquinol Formulation Suitable for Intravenous Use
December 16, 2018 Drug Delivery and Translational Research
Wehbe, M., Malhotra, A.K., Anantha, M., Lo, C., Dragowska, W.H., Dos Santos, N., and Bally, M.B.

Copper (II) Complexes of Bidentate Ligands Exhibit Potent Anti-Cancer Activity Regardless of Platinum Sensitivity Status
July 21, 2017 Investigational New Drugs
Wehbe, M., Lo, C., Leung, A.W.Y., Dragowska, W.H., Ryan, G.M., and Bally, M.B.

A Perspective – Can Copper Complexes be Developed as a Novel Class of Therapeutics?
July 4, 2017 Dalton Transactions
Wehbe, M., Leung, A., Abrams, M.J., Orvig, C., and Bally, M.B.

Development and Optimization of an Injectable Formulation of Copper Diethyldithiocarbamate, an Active Anticancer Agent
May 31, 2017 International Journal of Nanomedicine
Wehbe, M., Anantha, M., Shi, M., Leung, A.W.Y., Dragowska, W.H., Sanche, L, and Bally, M.B.

Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development
April 7, 2016 PLOS ONE
Wehbe, M., Anantha, M., Backstrom, I., Leung, A., Chen, K., Malhotra, A., Edwards, K., and Bally, M.B.